Paclitaxel and Epothilone Analogues, Anticancer Drugs

Analogue-Based Drug Discovery II

Volumn , Issue , 2010, Pages 243-267

  Erhardt, Paul W ^a   El Dakdouki, Mohammad ^a,b  

^a UNIVERSITY OF TOLEDO   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

ABDD; Apoptosis; Docetaxel; Epothilone analogues; Intravenous infusion; Ixabepilone; Multidrug resistance; NP pioneer drug; Paclitaxel; Pharmacological analogues; Stabilization of microtubules

Indexed keywords

EID: 84863751534     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527630035.ch10     Document Type: Chapter

References (89)

1. Fischer, J. and Ganellin, C.R. (eds) (2006) Analogue-Based Drug Discovery, Wiley-VCH Verlag GmbH, Weinheim.
2. Erhardt, P.W. and Matos, L. (2006) Selective beta-adrenergic receptorblocking agents, in Analogue-Based Drug Discovery (eds J. Fischer and C.R. Ganellin), Wiley-VHC Verlag GmbH, Weinheim, pp. 193-232.
3. Ganesan, A. (2008) The impact of natural products upon modern drug discovery. Chem. Biol., 12, 306-317.
4. Newman, D.J. and Cragg, G.M. (2007) Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 70, 461-477.
5. Ghosh, A.K. (2009) Harnessing nature.s insight: design of aspartyl protease inhibitors from treatment of drugresistant HIV to Alzheimer.s disease. J. Med. Chem., 52, 2163-2176.
6. McCullagh, M. (2008/2009) Natural product pharmaceuticals: the third generation. Drug Discov. World, Winter, 69-73.
7. Wall, M.E. (1993) Camptothecin and taxol, in Chronicles of Drug Discovery, vol. 3 (ed. D. Lednicer), American Chemical Society, Washington, DC, pp. 327-348.
8. George, G.I., Chen, T.T., Ojima, I., and Vyas, D.M. (eds) (1995) Taxane Anticancer Agents: Basic Science and Current Status, American Chemical Society,Washington, DC.
9. Suffness, M. (ed.) (1995) Taxol-: Science and Applications, CRC Press, New York.
10. Itokawa, H. and Lee, K.H. (eds) (2003) Taxus: The Genus Taxus, Taylor & Francis Group, New York.
11. Wall, M.E. and Wani, M.C. (1967) Abstracts of Papers, 153rd National Meeting of the American Chemical Society, Maimi Beach, FL, No. M-006.
12. Schiff, P.B., Fant, J., and Horwitz, S.B. (1979) Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665-667.
13. Chauvi-ere, G., Gu-enard, D., Picot, F., S-enilh, V., and Potier, P. (1981) Analyse structurale et etude biochimique de produits isoles de l.lf: Taxus baccata L (Taxac-ees). C.R. Acad. Sci. Paris II, 293, 501-507.
14. Hu, Z. and Erhardt, P.W. (1997) Utilization of a benzoyl migration to effect an expeditious synthesis of the paclitaxel side chain. Org. Process Res. Dev., 1, 387-390.
15. Wang, Z.M., Kolb, H.C., and Sharpless, K.B. (1994) Large-scale and highly enantioselective synthesis of the taxol C-13 side chain through asymmetric dihydroxylation. J. Org. Chem., 59, 5104-5105.
16. Holton, R.A. (1993) Metal alkoxides, US Patent 5,229,526 and 5,274,124.
17. Holton, R.A. and Biediger, R.J. (1993) Certain alkoxy substituted taxanes and pharmaceutical compositions containing them, US Patent 5,243,045. Other patents pending.
18. Holton, R.A., Biediger, R.J., and Boatman, P.D. (1995) Synthesis of taxol and taxotere, in Taxol-: Science and Applications (ed. M. Suffness), CRC Press, New York, pp. 97-121.
19. Skwarczynski, M., Sohma, Y., Noguchi, M., Kimura, M., Hayashi, Y., Hamada, Y., Kimura, T., and Kiso, Y. (2005) No auxiliary, no byproduct strategy for watersoluble prodrugs of taxoids: scope and limitation of O-N intramolecular acyl and acyloxy migration reactions. J. Med. Chem., 48, 2655-2666.
20. http://www.epa.gov/greenchemistry/ pubs/pgcc/winners/gspa04.html(2004).
21. McGuire, W.P., Rowinsky, E.K., Rosenshein, N.B., Grumbine, F.C., Ettinger, D.S., Armstrong, D.K., and Donehower, R.C. (1989) Taxol: a unique antineoplasticagentwithsignificantactivity in advanced ovarian epithelial neoplasms. Ann. Intern. Med., 111, 273-279.
22. Holmes, F.A., Walters, R.S., Theriault, R.L., Raber, M.N., Bazdar, A.U., Frye, D.K., and Hortobagyi, G.N. (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst., 83, 1797-1805.
23. Verweij, J., Clavel, M., and Chevalier, B. (1994) Paclitaxel (Taxol-) and docetaxel (Taxotere-): not simply two of a kind. Ann. Oncol., 5, 495-505.
24. Weiss, R.B., Donehover, R.C., Wiernik, P.H., Ohnuma, T., Gralla, R.J., Trump, D.L., Baker, J., Jr., Van Echo, D.A., Von Hoff, D.D., and Leyland-Jones, B. (1990) Hypersensitivity reactions from taxol. J. Clin. Oncol., 8, 1263-1268.
25. Sparreboom, A., Van Tellingen, O., Nooijen, W.J., and Beijnen, J.H. (1996) Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle cremophor EL. Cancer Res., 56, 2112-2115.
26. Lee, E., Lee, J., Lee, I.H., Yu, M., Kim, H., Chae, S.Y., and Jon, S. (2008) Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J. Med. Chem., 51, 6442-6449.
27. Sarver, J.G., Klis, W., Byers, J., and Erhardt, P.W. (2002) Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6Gaccumulation in multidrug resistant breast cancer cells. J. Biomol. Screen., 7, 29-34.
28. Erhardt, P.W. (1997) The biochemical mechanism of paclitaxel: in pursuit of a microtubule binding site. Taxane J., 3, 36-42.
29. George, G.I., Boge, T.C., Cheruvallath, Z.S., Clowers, J.S., Harriman, G.C.B., Hepperle, M., and Park, H. (1995) The medicinal chemistry of taxol, in Taxol-: Science and Applications (ed. M. Suffness), CRC Press, New York, pp. 317-375.
30. Denis, J.N., Greene, A.E., Gu-enard, D., Gu-eritte-Voegelein, F., Mangatal, L., and Potier, P. (1988) A highly efficient, practical approach to natural taxol. J. Am. Chem. Soc., 110, 5917-5919.
31. Mangatal, L., Adeline, M.T., Gu-enard, D., Gu-eritte-Voegelein, F., and Potier, P. (1989) Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues. Tetrahedron, 45, 4177-4190.
32. Gu-enard, D., Gu-eritte-Voegelein, F., and Potier, P. (1993) Taxol and taxotere: discovery, chemistry, and structure-activity relationships. Acc. Chem. Res., 26, 160-167.
33. Herranz, E., Biller, S.A., and Sharpless, K.B. (1978) Osmium-catalized vicinal oxyamination of olefins by N-chloro-Nargentocarbamates. J. Am. Chem. Soc., 100, 3596-3598.
34. Gu-eritte-Voegelein, F., Gu-enard, D., Lavelle, F., Le Goff, M.T.,Mangatal, L., and Potier, P. (1991) Relationships between the structure of taxol analogues and their antimitotic activity. J. Med. Chem., 34, 992-998.
35. Lavelle, F., Fizames, C., Gu-eritte-Voegelein, F., Gu-enard, D., and Potier, P. (1989) Experimental properties of RP 56976, a taxol derivative. Proc. Am. Assoc. Cancer Res., 30, 2254.
36. Bissery, M.C., Gu-enard, D., Gu-eritte-Voegelein, F., and Lavelle, F. (1991) Experimental antitumor activity of taxotere (RP, 56976, NCS 628503), a taxol analogue. Cancer Res., 51, 4845-4852.
37. Gu-eritte-Voegelein, F., Gu-enard, D., Dubois, J., Wahl, A., Marder, R., Müller, R., Lund, M., Bricard, L., and Potier, P. (1995) Chemistry and structure-activity relationships of taxoids and modified skeletons, in Taxane Anticancer Agents: Basic Science and Current Status (eds G.I. George, T.T. Chen, I. Ojima, and D.M. Vyas), American Chemical Society, Washington, DC.
38. Figgitt, D.P. and Wiseman, L.R. (2000) Docetaxel: an update of its use in advanced breast cancer. Drugs, 59, 621-651.
39. Vyas, D.M., Wong, H., Crosswell, A.R., Casazza, A.M., Knipe, J.O.,Mamber, S.W., and Doyle, T.W. (1993) Synthesis and antitumor evaluation of water soluble taxol phosphates. Bioorg. Med. Chem. Lett., 3, 1357-1361.
40. www.thomsonhc.com; Drugs; Paclitaxel; Comparison Information (2009).
41. Erhardt, P.W., Khupse, R., Sarver, J.G., and Trendel, J.A., Prodrugs: strategic deployment, metabolic considerations and chemical design principles, inBurger.s Medicinal Chemistry, Drug Discovery and Development (ed. D. Abraham), John Wiley & Sons, Inc., Hoboken, NJ, Vol. 3, p. 103, (2010).
42. Erhardt, P.W. and El-Dakdouki, M., The multiple benefits of analog based drug discovery (ABDD): microtubule stabilizers as a case in point. J. Pure Appl. Chem., submitted.
43. Jordan, M.A. and Wilson, L. (2004) Microtubules as a target for anticancer drugs. Nature reviews. Cancer, 4, 253-265.
44. Hearn, B.R., Shaw, S.J., and Myles, D.C. (2006) Microtubule targeting agents. Comp. Med. Chem. II., 7, 81-110.
45. Feyen, F., Cachoux, F., Gertsch, J., Wartmann, M., and Altmann, K.H. (2008) Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization. Acc. Chem. Res., 41, 21-31.
46. Kingston, D.G.I. (2009) Tubulininteractive natural products as anticancer agents. J. Nat. Prod., 72, 507-515.
47. Myles, D.C. (2002) Emerging stabilizing agents for cancer chemotherapy. Ann. Rep. Med. Chem., 37, 125-132.
48. Gerth, K., Bedorf, N., Hoefle, G., Irschik, H., and Reichenbach, H. (1996) Antibiotics from gliding bacteria. 74. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria): production, physico-chemical and biological properties. J. Antibiot., 49, 560-563.
49. Bollag, D.M., McQueney, P.A., Zhu, J., Hensens, O., Koupal, L., Liesch, J., Goetz, M., Lazarides, E., and Woods, C.M. (1995) Epothilones, a new class of microtubulestabilizing agents with a taxol-like mechanism of action. Cancer Res., 55, 2325-2333.
50. Gunasekera, S.P., Gunasekera, M., Longley, R.E., and Schulte, G.K. (1990) Discodermolide: a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissolute. J. Org. Chem., 55, 4912-4915;Correction: J. Org. Chem., 1991, 56, 1346.
51. Longley, R.E., Caddigan, D.,Harmody, D., Gunasekera, M., and Gunasekera, S.P. (1991) Discodermolide: a new, marinederived immunosuppressive compound. I. In vitro studies. Transplantation, 52, 650-656.
52. Longley, R.E., Caddigan, D.,Harmody, D., Gunasekera, M., and Gunasekera, S.P. (1991) Discodermolide: a new, marinederived immunosuppressive compound. II. In vivo studies. Transplantation, 52, 656-661.
53. Longley, R.E., Gunasekera, S.P., Faherty, D., Mclane, J., and Dumont, F. (1993) Immunosuppression by discodermolide. Ann. N.Y. Acad. Sci., 696, 94-107.
54. Hung, D.T., Nerenberg, J.B., and Schreiber, S.L. (1994) Distinct binding and cellular properties of synthetic (+)- and (-)-discodermolides. Chem. Biol., 1, 67-71.
55. terHaar, E., Kowalski, R.J.,Hamel, E., Lin, C.M., Longley, R.E., Gunasekera, S.P., Rosenkranz, H.S., and Day, B.W. (1996) Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry, 35, 243-250.
56. Kalesse, M. (2000) The chemistry and biology of discodermolide. ChemBioChem, 1, 171-175.
57. Nerenberg, J.B., Hung, D.T., Somers, P.K., and Schreiber, S.L. (1993) Total synthesis of the immunosuppressive agent (-)-discodermolide. J. Am. Chem. Soc., 115, 12621-12622.
58. Smith, A.B., III, Kaufman, M.D., Beauchamp, T.J., LaMarche, M., and Arimoto, H. (1999) Gram-scale synthesis of (+)-discodermolide. Org. Lett., 1, 1823-1826.
59. Mickel, S.J. (2004) Toward a commercial synthesis of (+)-discodermolide. Curr. Opin. Drug Discov. Dev., 7, 869-881.
60. Lindel, T., Jensen, P.R., Fenical,W., Long, B.H., Casazza, A.M., Carboni, J., and Fairchild, C.R. (1997) Eleutherobin, a new cytotoxin that mimics paclitaxel (taxol) by stabilizing microtubules. J. Am. Chem. Soc., 119, 8744-8745.
61. Long, B.H., Carboni, J.M., Wasserman, A.J., Cornell, L.A., Casazza, A.M., Jensen, P.R., Lindel, T., Fenical,W., and Fairchild, C.R. (1998) Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). Cancer Res., 58, 1111-1115.
62. Corley, D.G., Herb, R., Moore, R.E., Scheuer, P.J., and Paul, V.J. (1988) Laulimalides. New potent cytotoxic macrolides from a marine sponge and a nudibranch predator. J. Org. Chem., 53, 644-646.
63. Jefford, C.W., Bernardinelli, G., Tanaka, J.I., and Higa, T. (1996) Structures and absolute configurations of the marine toxins, latrunculin A and laulimalide. Tetrahedron Lett., 37, 159-162.
64. Mooberry, S.L., Tien, G.,Hernandez, A.H., Plubrukarn, A., and Davidson, B.S. (1999) Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res., 59, 653-660.
65. Pryor, D.E., O. Brate, A., Bilcer, G., Diaz, J.F., Wang, Y., Wang, Y., Kabaki, M., Jung, M.K., Andreu, J.M., Ghosh, A.K., Giannakakou, P., andHamel, E. (2002)The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry, 41, 9109-9115.
66. Mulzer, J. and Ohler, E. (2001) An intramolecular case of Sharpless kinetic resolution: total synthesis of laulimalide. Angew. Chem. Int. Ed., 40, 3842-3846.
67. Paterson, I., De Savi, C., and Tudge, M. (2001) Total synthesis of the microtubulestabilizing agent (-)-laulimalide. Org. Lett., 3, 3149-3152.
68. Ghosh, A.K. and Wang, Y. (2000) Total synthesis of (-)-laulimalide. J. Am. Chem. Soc., 122, 11027-11028.
69. West, L.M., Northcote, P.T., and Battershill, C.N. (2000) Peloruside A: a potent cytotoxic macrolide isolated from the New Zealand marine sponge Mycale sp. J. Org. Chem., 65, 445-449.
70. Hood, K.A., West, L.M., Rouwe, B., Northcote, P.T., Berridge,M.V.,Wakefield, S.J., and Miller, J.H. (2002) Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res., 62, 3356-3360.
71. Nicolaou, K.C., Roschangar, F., and Vourloumis, D. (1998) Chemical biology of epothilones. Angew. Chem. Int. Ed., 37, 2014-2045.
72. Harris, C.R. and Danishefsky, S.J. (1999) Complex target-oriented synthesis in the drug discovery process: a case history in the dEpoB series. J. Org. Chem., 64, 8434-8456.
73. Altmann, K.H., Bold, G., Caravatti, G., Florsheimer, A., Guagnano, V., and Wartmann, M. (2000) Synthesis and biological evaluation of highly potent analogues of epothilones B and D. Bioorg. Med. Chem. Lett., 10, 2765-2768.
74. Wartmann, M. and Altmann, K.H. (2002) The biology and medicinal chemistry of epothilones. Curr. Med. Chem. Anticancer Agents, 2, 123-148.
75. Altmann, K.H. (2003) Epothilone B and its analogs: a new family of anticancer agents. Mini Rev. Med. Chem., 3, 149-158.
76. Stachel, S.J., Biswas, K., and Danishefsky, S.J. (2001) The epothilones, eleutherobins, and related types of molecules. Curr. Pharm. Des., 7, 1277-1290.
77. Fumoleau, P., Coudert, B., Isambert, N., and Ferrant, E. (2007) Novel tubulintargeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann. Oncol., 18, 9-15.
78. Altmann, K.H. (2005) Recent developments in the chemical biology of epothilones. Curr. Pharm. Des., 11, 1595-1613.
79. Goodin, S., Kane, M.P., and Rubin, E.H. (2004) Epothilones: mechanism of action and biologic activity. J. Clin. Oncol., 22, 2015-2025.
80. Kingston, D.G.I. (2004) What makes epothilones stick?Chem. Biol., 11, 153-155.
81. Jimenez-Barbero, J., Amat-Guerri, F., and Snyder, J.P. (2002) The solid state, solution and tubulin-bound conformations of agents that promote microtubule stabilization. Curr. Med. Chem. Anticancer Agents, 2, 91-122.
82. Winkler, J.D. and Axelsen, P.H. (1996) A model for the taxol (paclitaxel)/epothilone pharmacophore. Bioorg. Med. Chem. Lett., 6, 2963-2966.
83. Ojima, I., Chakravarty, S., Inoue, T., Lin, S.,He, L., Horwitz, S.B., Kuduk, S.D., and Danishefsky, S.J. (1999) A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc. Natl. Acad. Sci. USA, 96, 4256-4261.
84. He, L., Jagtap, P.G., Kingston, D.G.I., Shen, H.J., Orr, G.A., and Horwitz, S.B. (2000) A common pharmacophore for Taxol and the epothilones based on the biological activity of a taxane molecule lacking a C-13 side chain. Biochemistry, 39, 3972-3978.
85. Giannakakou, P., Gussio, R., Nogales, E., Downing, K.H., Zaharevitz, D., Bollbuck, B., Poy, G., Sackett, D., Nicolaou, K.C., and Fojo, T. (2000)Acommon pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. USA, 97, 2904-2909.
86. Nettles, J.H., Li, H., Cornett, B., Krahn, J.M., Snyder, J.P., and Downing, K.H. (2004) The binding mode of epothilone A on a,b-tubulin by electron crystallography. Science, 305, 866-869.
87. Borzilleri, R.M., Zheng, Z., Schmidt, R.J., Johnson, J.A., Kim, S.H., DiMarco, J.D., Fairchild, C.R., Gougoutas, J.Z., Lee, F.Y.F., Long, B.H., and Vite, G.D. (2000) A novel application of a Pd(0)-catalyzed nucleophilic substitution reaction to the regio- and stereoselective synthesis of lactam analogues of the epothilone natural products. J. Am. Chem. Soc., 122, 8890-8897.
88. Hegde, S. and Schmidt, M. (2008) To market, to market-2007. Ann. Rep. Med. Chem., 43, 455-497.
89. Erhardt, P.W., Drug discovery, in Advanced Pharmacology (eds K.A. Bachmann, M. Hacker, and W. Messer), Elsevier, Oxford, UK, p. 175, (2009).